Open AccessReal-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma
Author(s) -
Nika De Wilde,
Luisa Vonghia,
Sven Francque,
Thomas De Somer,
Ali Bagdadi,
Eva Staub,
Jasper Lambrechts,
AnaMaria Bucalau,
Gontran Verset,
Christophe Van Steenkiste
Publication year - 2022
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v14.i8.1608
Subject(s) - medicine , nivolumab , durvalumab , response evaluation criteria in solid tumors , population , retrospective cohort study , regimen , adverse effect , bevacizumab , oncology , hepatocellular carcinoma , cancer , progressive disease , disease , chemotherapy , immunotherapy , environmental health
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. The landscape of the systemic treatment for advanced HCC is changing quickly, and recently, the standard of care became either atezolizumab plus bevacizumab or tremelimumab plus durvalumab in the single tremelimumab regular interval durvalumab regimen. Nivolumab monotherapy has proven to be effective sometimes for advanced HCC and could be a valuable treatment option for patients outside current treatment indications and reimbursement criteria for the standard of care. This is a particular population of interest.